News & Updates

Show Multimedia Only
Avacincaptad pegol slows geographic atrophy progression
Avacincaptad pegol slows geographic atrophy progression
1 hour ago byStephen Padilla

Patients with noncentre point-involving geographic atrophy (GA) who receive avacincaptad pegol (ACP) 2 mg every month (EM) or every other month (EOM) show a persistent decrease in GA growth over 2 years relative to sham therapy, with no new safety signals, according to the GATHER2 study.

Avacincaptad pegol slows geographic atrophy progression
1 hour ago